Arrowhead Pharmaceuticals, Inc.
ARWRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeArrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. With a market capitalization of $12.02B, it sits in large-cap territory. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.
Market Cap
$12.02B
Beta
1.28
P/E (TTM)
—
P/E (Fwd)
-17.62
EPS (TTM)
$-2.28
EPS (Fwd)
$-4.83
ROE
-55.2%
ROA
-8.1%
Cash
$1.60B
Total Debt
$1.38B
Free CF
-$48.6M
52W Change
198.9%
Annual Financials
Cash vs Debt
Where ARWR stands vs its 150-day and 200-day moving averages
As of the August 18, 2026 close, ARWR finished 23.31% above its 150-day moving average ($71.93) and 30.63% above its 200-day moving average ($67.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ARWR overbought or oversold?
At the August 18, 2026 close, ARWR's RSI(14) was 56.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $1.60B in cash comfortably exceeding the $1.38B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$48.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -55.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $243.2M to $829.4M.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing ARWR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.